scholarly journals Red blood cell blood transfusions and occurrence of adverse reactions: a retrospective study in 101 dogs

2019 ◽  
pp. 468-469
Author(s):  
Consuelo Alonzi ◽  
Simon Tappin
Injury ◽  
2013 ◽  
Vol 44 (6) ◽  
pp. 747-750 ◽  
Author(s):  
Assaf Kadar ◽  
Ofir Chechik ◽  
Eldad Katz ◽  
Itay Blum ◽  
Gabrielle Meghiddo ◽  
...  

2016 ◽  
Vol 52 (3) ◽  
pp. 144-148 ◽  
Author(s):  
Megan Davis ◽  
Kiko Bracker

ABSTRACT Antifibrinolytic drugs are used to promote hemostasis and decrease the need for red blood cell transfusion. Medical records of 122 dogs that were prescribed either oral or intravenous aminocaproic acid between 2010 and 2012 were evaluated retrospectively. Of the 122 dogs, three experienced possible drug-related adverse effects. No significant differences were identified between dogs that experienced adverse effects and those that did not and the possible adverse effects noted were all minor. All dogs that received packed red blood cell transfusions were evaluated for correlations between baseline packed cell volume or dose of red blood cells and aminocaproic acid dose and no correlation was identified. Dogs that received aminocaproic acid as a treatment for active bleeding were divided by cause of hemorrhage into the following groups: neoplastic, non-neoplastic, and unknown. No significant differences in aminocaproic acid dose or the percentage of patients requiring a blood transfusion were identified between groups.


2021 ◽  
Vol 49 (5) ◽  
pp. 365-372
Author(s):  
Cyril Pernod ◽  
◽  
Laurie Fraticelli ◽  
Guillaume Marcotte ◽  
Bernard Floccard ◽  
...  

2021 ◽  
pp. bmjspcare-2020-002582
Author(s):  
Guillaume Robert ◽  
Celine Chappe ◽  
Ana Ferreira ◽  
Elisabeth MC Ewan ◽  
Sara Calmanti

Should indication for transfusion in paediatric palliative care be based on the child’s perspective rather than the biological results? An 8-year-old boy presenting a relapse of a stage IV neuroblastoma received regular blood transfusions. A severe exophtalmia led the doctors to question the transfusion strategy. Over 7.5 months, the child received 56 red blood cell units and 31 platelet units. He was hospitalised 50 times. Indication for blood test and transfusion may be regularly and collegially reassessed. Transfusion needs in a palliative strategy can be as high as in a curative strategy. Practices, benefits but also ethical and public health dimensions should be more studied.


Blood ◽  
2012 ◽  
Vol 120 (21) ◽  
pp. 4383-4383
Author(s):  
Sabine Sipurzynski-Budraâ ◽  
Petra Sovinz ◽  
Gerhard Lanzer ◽  
Katharina Schallmoser

Abstract Abstract 4383 Background: Sickle cell disease, an autosomal recessive genetic blood disorder, is caused by abnormal hemoglobin (Hb) due to a substitution of valine by glutamic acid at β6 (HbS). Typical adverse events are vaso-occlusive crises due to obstruction of capillaries causing ischemia, pain and organ damage, as well as enhanced hemolysis and frequent hemolytic crises. Further complications may include acute chest syndrome and stroke. To prevent long-term sequelae, repeated blood transfusions are necessary to decrease erythropoiesis of sickle cells. We suggest that it may be more effective to reduce sickle cells by a red blood cell (RBC) exchange, which is advantageous in avoiding iron overload by transfusions. Patient and Methods: We report on a 10 year old boy suffering from the homozygote form of sickle cell anemia. RBC exchange was performed using the Spectra Optia® Apheresis System (Caridian BCT vers.5) when the patient's hematocrit (hct) was less than 26%. Traditional RBC exchange was modified by a depletion phase to improve efficacy. During this phase (= isovolemic hemodilution) HbS-containing red cells were removed without admixture of donor red cells by using plasma as replacement fluid. To prevent adverse side effects caused by adenine, the additive solution in the RBC concentrates was replaced by saline solution or plasma. Results: The therapeutic apheresis was feasible repeatedly via peripheral venous access (flow: 30 ± 3 mL/min, anticoagulant (AC) infusion rate 0.8 – 1.1mL/min/L total blood volume, inlet: AC ratio 13: 1) and no adverse side effects were observed. The median interval between the procedures was 42 ± 2 days. The depletion time (replacement fluid: plasma) was 25 ± 5 min, the exchange time 90 ± 10 min. The hct value at the end of the procedure was between 33 and 34%, the fraction of the patient's remaining cells (FCR) was 24 ± 2% (calculated by the device). Conclusion: RBC exchange with the Optia Spectra® System is a fast and safe method for reducing sickle cells, particularly efficient in combination with a depletion phase. Compared to blood transfusions alone, the HbS concentration declines rapidly by depleting and replacing sickle cells with normal RBCs without hyperviscosity or iron overload. However, only long-term surveillance and treatment of a larger patient collective will show whether it is possible to prevent vaso-occlusive crises and organ damage over a longer time period. Disclosures: No relevant conflicts of interest to declare.


2011 ◽  
Vol 31 (1) ◽  
pp. 25-34 ◽  
Author(s):  
Tara Ann Collins

Anemia, which is prevalent in critically ill patients, often requires frequent blood transfusions. These blood transfusions are not without risks. A critical review of 6 studies shows an association between red blood cell transfusion and increased mortality. However, when disease state was adjusted for in 2 studies, researchers found that red blood cell transfusion correlated with decreased mortality. Thus further research, particularly on leukoreduction and age of stored blood, must be done before a change in practice can be implemented. It is vital that nurses stay current on this research in order to improve patients’ outcomes.


Sign in / Sign up

Export Citation Format

Share Document